DENALI THERAPEUTICS INC (DNLI:NASDAQ)
$20.77 0.56 (2.7709%)
Analysed DENALI THERAPEUTICS INC (DNLI:NASDAQ) News Sources
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
18-05-2026
fool.com
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
21-05-2026
yahoo.com
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial
21-05-2026
stocktwits.com
Parkinson’s drug from Biogen, Denali comes up short
22-05-2026
biopharmadive.com
Stocks Supported by US-Iran Peace Deal Optimism
22-05-2026
barchart.com
Stocks Climb on US-Iran Peace Hopes and Strength in Chipmakers
22-05-2026
barchart.com
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
22-05-2026
yahoo.com
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks
22-05-2026
yahoo.com
Stocks Settle Higher on Iran Peace Hopes and Tech Strength
22-05-2026
barchart.com
Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says
26-05-2026
yahoo.com
What is the current price of DENALI THERAPEUTICS INC (DNLI:NASDAQ)?
The current price of DENALI THERAPEUTICS INC (DNLI:NASDAQ) is $20.77.
DENALI THERAPEUTICS INC (DNLI:NASDAQ) absolute price change since previous trading day?
The absolute price change of DENALI THERAPEUTICS INC (DNLI:NASDAQ) since the previous trading day is $0.56.
DENALI THERAPEUTICS INC (DNLI:NASDAQ) percentage price change since previous trading day?
The percentage price change of DENALI THERAPEUTICS INC (DNLI:NASDAQ) since the previous trading day is 2.7709%.
What is the most recent average sentiment score for DENALI THERAPEUTICS INC (DNLI:NASDAQ)?
The most recent average sentiment score for DENALI THERAPEUTICS INC (DNLI:NASDAQ) is 55 out of 100.
What is the most recent average sentiment for DENALI THERAPEUTICS INC (DNLI:NASDAQ)?
The most recent sentiment for DENALI THERAPEUTICS INC (DNLI:NASDAQ) is .
SEC-8K** Filing Available For DENALI THERAPEUTICS INC (DNLI:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.